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Endotoxic lipopolysaccharides (LPS)  1 have a potent ability to interact with 
complement (C) during incubation in normal mammalian serum (2, 3). Lesions 
indicative of terminal  C  component activation appear  on LPS  (2,  4)  while, 
concomitantly,  C  components  are  consumed  and  C-dependent  biologically 
active  by-products  (neutrophil  chemotactic  factor  and  anaphylatoxin)  are 
generated (5-7). As a  result, it has been postulated that certain toxicities in- 
duced by endotoxins may be mediated via the C system. (8, 9). 
One striking feature of the LPS-C interaction in fresh guinea pig serum is 
that marked consumption of the six terminal  C  components (C3-C9)  occurs, 
even though minimal consumption of the earlier-acting C components (C1, C4, 
and  C2)  is detected (5). When hyperimmune serum is added to the reaction 
mixtures, pronounced consumption of C1,  C4,  and  C2,  as  well as  C3-C9,  is 
readily seen  (3). This has  raised  the question of whether LPS  activates the 
C3-C9 components via the usual pathway of antibody-C1-C4-C2  (10-12)  or 
via an alternative pathway. 
Hence, the present investigation was concerned with the role of the factors 
usually responsible for activation of C, classical humoral antibodies, in initiating 
the LPS-C interaction. The requirement of antibody for the consumption of C 
by LPS was  investigated.  Initial  attempts  to deplete  antibodies  to LPS  by 
selective absorptions  proved noncritical,  in  part  because  of solubilization  of 
LPS (2). Hence, the LPS-C interaction was studied in bovines, porcines, and 
humans  with developmental agammaglobulinemia  (13-15),  chickens with ex- 
perimental agammaglobulinemia (16),  and humans with agammaglobulinemia 
syndromes (17). 
* Presented in part to the American Society  for Clinical Investigation, May 7, 1968 (1). 
x The following abbreviations are used in  this paper: AGG, agammaglobulinemia; BSA,  . 
bovine serum albumin; CVF, cobra venum factor; and LPS, endotoxic  lipopolysaccharide. 
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Materials and Methods 
Endotoxie  lipopolysaccharides  (LPS).--Biologically  active LPS were prepared from  Veil- 
lonella alcaleseens (2), wild type Salmonella  minnesota ~ (4) and the R595 mutant of Salmonella 
minnesota 2  (4)  by  the phenol-water  extraction procedure  of  Westphal  and  Liideritz  (18). 
Serratia  mareescens LPS  3 (3) was prepared by the trichloroacetic acid extraction procedure of 
Boivin et al. (19). 
Cobra venom factor  (CVF).~he  complement "inactivating" factor was  extracted from 
Naja haje Egyptian cobra venom by a modification (20) of the procedure by Nelson (21). 
Immune complexes.--Crystalline  bovine serum albumin (BSA) was obtained from Pentex 
Inc., Kankakee, Ill. Rabbit anti-BSA was obtained from Hyland Laboratories, Los Angeles, 
Calif., and contained 240 #g antibody nitrogen per ml. BSA and rabbit anti-BSA were reacted 
at equivalence for 24 hr at 4°C in the presence 0.01 M EDTA. The precipitate was washed twice 
in EDTA-saline and resuspended in saline. Final protein concentrations were determined by 
the assay of Lowry et al. (22). 
Immunoglobulin-Dejicient  Sera.  Sera  from  several  different  types  of  immunoglobulin- 
deficiency states were available for study. Serum from newborn humans was separated from 
cord blood samples.  Serums from newborn bovine and pigs were  taken immediately post- 
partum prior to any ingestion of colostrum. Precolostral serum specimens from representative 
pathogen-free, disease-free agammaglobulinemic Minnesota miniature piglets were generously 
provided by Drs. Y. B. Kim and D. W. Watson (14). Sera from chickens with agammaglobu- 
linemia experimentally induced by bursectomy and irradiation in the newborn period  (16) 
were kindly provided by Drs. G. Alm and R. D. A. Peterson. Sera from humans with agamma- 
globulinemic syndromes were collected from patients previously described (23, 24) at the Uni- 
versity of Minnesota Hospitals. 
Methods.--Assays of hemolytic C in human (25), bovine (24), porcine (26), and chicken (27) 
serum, and assays for neutrophil chemotactic factor (6) and anaphylatoxin (7) in piglet serum 
were performed as previously described. Preincubations of LPS and the test sera, unless other- 
wise described, were performed with 0.1 ml of test serum in 1.0 ml of Veronal-buffered saline, 
supplemented with calcium and magnesium ions  (10). 
Formation of an LPS-X intermediate capable of fixing the terminal C components has been 
described by Shin et al. (28). In the present adaptation, 300 #g V. alcaleseens LPS in 0.5 ml of 
buffer was incubated with 0.5 ml  of human serum at 37°C  for intervals of 15-120 min. The 
mixtures were centrifuged at 13,000  rpm for 45 rain at 0°C, the supernates discarded, and the 
LPS-serum complexes  resuspended in 0.5 ml of buffer. These were added  to  1.5 ml of 1:10 
guinea pig C-EDTA, and the mixtures incubated at 37°C for 60 rain; the amounts of terminal 
C components (C3-C9) fixed during this incubation were determined in the usual way (25). 
Quantitation of the immunoglobulins in the human sera was performed by radial diffusion 
assay  (29).  Assays for  immunoglobulin  (14),  phage  neutralizing capacity  (14),  and  sheep 
hemolysins (30)  also were performed as previously described. 
RESULTS 
I.  Developmental  Agammaglobulinemia.--Newborn  and gestational members 
of  several  species  are  known  to  be  retarded  in  their  development  of  gamma 
globulins  generally  and  specific  antibodies  in  particular.  Therefore,  we  first 
tested the ability of LPS  to fix C  in several of these sera. 
2 Generously provided  by Dr.  O.  Liideritz. 
3 Generously provided by Dr. A. Nowotny. GEWlIRZ ET  AL.  819 
Human: Human newborns have deficient serum concentrations of IGM, IGA, 
and the C-fixing sheep cell hemolysin, while they have IGG titers generally as 
great or greater than their mothers at the time of birth. (Table I). Nonetheless, 
incubation  of V. alcalescens LPS with these sera led to consumption of large 
amounts of hemolytic C  (Table I, Fig. 1). 
Bovine:  The bovine has  a  six layered placenta  which  acts  as  a  barrier  to 
transfer of maternal proteins to the fetus; hence,  the bovine embryo is more 
deprived of gamma globulins than is the human  (13). This can be seen in the 
gamma globulin and sheep cell hemolysin titers shown in Table II. When these 
sera were preincubated at 37°C with LPS derived from any of four organisms 
(S. marcescens,  V. alcalescens, S. minnesota  wild type, and S. minnesota R595 
mutant), pronounced consumption of C ensued (Table II). Hence, LPS had the 
capacity to deplete  C  even in  these  immunoglobulin-deficient sera.  Even  an 
TABLE I 
C Consumpt~nbyEndotoxicLPSinPair~  HumanCordandMaterndSerum Sampl~ 
IGG  IGA  IGM  IGD  Sheep  Total C  Available C 
Source of sample  mg/lO0 ml serum  hemolysin  Ctt6o/ml  consumedLPs  by 
unit~ml  % 
Cord 1  1400  7  7  2  2  15  >80 
Cord 2  940  6.5  9  0.1  2  25  66 
Cord 3  970  5  8  1  2  26  >80 
Maternal 1  1300  217  168  5.3  240  30  47 
Maternal 2  940  135  87  2.7  130  43  39 
Maternal 3  940  190  82  16.5  910  42  50 
LPS devoid of the O antigen (the R595 mutant of S. minnesota),  which lacked 
the  antigen  against  which  natural  antibodies  frequently  are  directed,  could 
effectively consume C  in these sera. C  consumption was seen both in embryo 
sera (the 65 cm stage, corresponding to the 3rd trimester)  and in precolostra| 
specimens of serum. 
Piglet: The pig has a placenta which is even less permeable to passive transfer 
of maternal proteins than is that of the bovine (31).  Specimens of pig embryo 
serum  was  taken  on  the  77th  and  90th  day of the  115-120  day gestational 
period, as well as in the immediate postnatal period prior to colostral feedings. 
These  sera  were  found  to  be  devoid  of  gamma  globulins  by  immunoelec- 
trophoresis,  and  to have either  absent  or trivial  amounts  of  "natural"  anti- 
bodies against the rasp-2 phage and the sheep red cell (Table III). Nonetheless, 
when reacted with LPS from four separate bacterial species, pronounced con- 
sumption of C was observed. 
Watson-Kim piglet model: The isolation of the porcine embryo from certain 820  COMPLEMENT  INTERACTIONS  WITH  LPS 
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of the maternal proteins led Watson and Kim to establish a methodology for 
deriving  agammaglobulinemic newborn  piglets,  which  they have  extensively 
characterized (14). These investigators worked with the disease-free, pathogen- 
free Minnesota miniature pig colony and were able to obtain precolostral blood 
samples from embryos which had less than 2.5  X  10  -6 mg gamma globulin per 
100  ml  of serum,  while  the corresponding  maternal  sera had  approximately 
5 X  103 mg gamma globulin per 100 ml serum. When the effects of various LPS 
preparations upon the C activity of these sera were tested, it was again found 
that each was effectively C-consuming (Table IV): substantial depletion of C 
occurred during the preincubation periods. 
Previous findings indicated that the consumption of C  by LPS leads to the 
generation  of neutrophil  chemotactic factors and  anaphylatoxins from  the  C 
TABLE II 
C Consumption by Endotoxic LPS in Immunoglobulin-Deficient Sera of Fetal and  Newborn 
Bovine 
Available C consumed 
Sheep  Total C  S.  S.  Age of animal  y-globulin  hemolysin  S. marces-  V. alcales-  minnesota  minnesota 
cens  cens  (R595  (wild 
mutant)  type) 
mg/ lO0 ml  units/ml  %  %  %  % 
blood 
65 cm embryo  <50  <2  25  >80  80  80  80 
Newborn  < 50  < 2  42  > 44  66  60  62 
Adult  620  --  230  > 70  > 70  > 70  > 70 
Adult  620  150  242  >65  38  33  >65 
Adult  620  175  228  >65  61  51  >65 
system in fresh guinea pig serum (6,  7). We tested whether these factors could 
also be derived in these agammaglobulinemic sera. As is shown in Figs. 2 and 5, 
there was clear development of both these factors. However, the total amount of 
factor generated  in the newborn sera always was less than that generated in 
comparable amounts of adult sera. 
We conclude that in sera from the available models of developmental agam- 
maglobulinemia, LPS  can  effectively induce  consumption  of  C  and,  further, 
bring  about  the  generation  of  anaphylatoxin  and  neutrophil  chemotactic 
activities. 
It should be noted that new borns in each of the three species tested had  C 
titers lower than those of their mothers. This disparity in C  available made it 
difficult to compare the newborn and adult sera quantitatively with respect to 
their relative abilities to respond to given amounts of LPS with  C  depletion. 
On the basis of the per cent of available C consumed, the degree of C depletion 822  COMPLEMENT  INTERACTIONS  WITH  LPS 
in the immunoglobulin-deficient new borns was similar to that  observed in the 
nearly normal globulinemic adults.  However,  on an absolute basis, since  there 
was much  less C  available,  less total units of C  were fixed. 
This deficiency of the newborn sera was dramatized by their decreased ability 
TABLE  III 
C Consumption  by Endoto.vic LPS in Immunoglobulin-Defident  Sera of Fetal and Newborn Pigs 
Available C consumed 
-~lobulin Phage (rasp-2)  S. 
,  r~u-  neutralizing  Sheep  Total C  V.  S.  minne- 
Age of animal  noelec-  activity  hemolysin  S.  minnesota  sota 
tropho-  (K values)  marcescens aleales-  nesis)  cens  (R595  (wild 
mutant)  type) 
units/mr  nnits/ml  %  %  %  % 
77 day embryo  0*  <0.001  <2  14  >60  14  --  -- 
90 day embryo  0  0.006  <2  28  >80  --  >80  27 
3 day newborn  0  --  --  55  64  53  --  -- 
Adult  +  0.081  3100  133  72  81  87  56 
Adult  +  0.079  540  160  69  79  67  43 
Adult  +  0.052  175  134  55  74  83  51 
* 0 indicates absence, +  indicates presence of -r-globulin. 
TABLE  IV 
C  Consumption  by Endotoxic  LPS in  Immunoglobulin-Deficient  Preeolostral  Miniature Piglet 
Serum 
Available C consumed 
Sheep  S.  S.  Age of animal  7-Globulin  hemolysin  Total G  S.  V.  •  .  minnesota 
ms  n n e$o  ~a  marcescens  alcalescens  (wild 
(R595)  type) 
mg/lO0 ml blood  units/ml  unlts/ml  %  %  %  % 
Newborn  <2.5 )< 10  -~  --  17  >75  >75  --  -- 
Newborn  <2.5 X  10-6  <10  23  >78  >78  >78  >78 
Sow  5 X  l0  s  --  44  66  75  --  -- 
Sow  5 X  l0  s  875  57  40  74  54  67 
to  generate  neutrophil  chemotactic  factor(s)  and  anaphylatoxin(s),  and  (see 
below) by their decreased ability to form, upon incubation with LPS,  an inter- 
mediate  capable  of  inducing consumption  of  the terminal  C  components  in  a 
mixture of serum-EDTA. 
It  is  not  yet  clear  whether  the  C  depletion  observed  in  the  newborn  sera 
results from  a  very efficient use  of subdetectable  amounts  of immunoglobulin, 
or  whether  alternative  nonimmunoglobulin  factors  are  involved  in  initiating 
these reactivities. GEWURZ ET  AL.  823 
H.  Experimental A gammaglobulinemia in the Chick.--In the past 4 years, the 
experiments of Cooper et al.  (16) have resulted in a means for experimentally 
producing an agammaglobulinemic animal. This was  achieved by removal of 
the bursa of Fabricius in the chicken, followed by X-irradiation.  Animals  so 
pretreated  were  available  for study.  Such  chickens have  been  shown  to  be 
LPS  :  Endotoxin  P 
H = Histamine  +  0.5 
LPS  ~( 
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FIG. 2.  Demonstration of factor(s) which contract the guinea pig ileum after the addition 
of 0.2 ml of an incubation mixture containing 200 #g of V. alcalescens LPS in 1.0 ml of serum 
from  (A)  precotostral pathogen-free, disease-free piglet and  (B)  postpartum maternal pig 
(generously provided by Drs. Y. B. Kim and*D. W. Watson). 
TABLE  V 
C Consumption by Endotoxic Lipopolysaccharide in Agammaglobullnemic 
(Bursectomized-Irradiated) Chicken Serum 
Available C  Source of sample  -/-globulin  Total C  consumed  by LPS 
mg/lO0 mI blood  units/ml  % 
Normal  1000  100  95 
Bursectomized-irradiated  2  180  94 
unable to respond with  antibody formation,  even after repeated stimulation, 
to a variety of antigens including the Brucella abortus organism. Representative 
birds had less  than 2 mg gamma globulin per 100 ml blood detectable by im- 
munodiffusion against  anti-chicken gamma globulin  antiserum  (compared to 
an age-matched normal with 1000 mg gamma globulin per 100 ml blood), yet 
had clearly detectable C  activity. When reacted with LPS, pronounced con- 
sumption of C  ensued (Table V).  Therefore, LPS  effectively consumed  C  in 
the sera of animals with the presently available model of experimental agamma- 824  COMPLEMENT INTERACTIONS  WITH  LPS 
globulinemia,  as  well  as  in  the  available models  of developmental  agamma- 
globulinemia (AGG). 
III.  Complement Consumption in the Sera  of Humans  with Agammaglobu- 
linemia Syndromes.--Since  the introduction of penicillin to clinical medicine, it 
has become apparent that certain AGG states exist in man which are associated 
with  a  propensity  to  infection.  Sera  from certain  of  these  individuals  were 
available for study. 
The marked deficiency of gamma globulins in a group of 11 such patients is 
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FIG. 3.  C consumption by 25/~g of V.  e]calescens  LPS, 2 #g of cobra venom factor C, and 
50/zg of washed preformed immune complexes prepared at equivalence with bovine serum 
albumin and rabbit antiserum, during preincubation for 1 hr at 37°C in 1.0 ml of buffered 
solution containing 0.2 ml of serum from agammaglobulinemic and normal individuals. The 
per cent of the available hemolytic complement activity consumed is indicated in the figure. 
represented in Fig. 1A by the greatly decreased titer of natural antibody against 
sheep erythrocytes, compared to the readily demonstrable titer of such C-fixing 
antibodies in normal children. When 20  /ag S. marcescens LPS was interacted 
with these sera, consumption of C  dearly ensued, despite the immunoglobulin 
deficiency (Fig. 1B) ; however, the per cent and the total amount of C consumed 
was less than that consumed by normal individuals. It is not yet clear whether 
multiple pathways to C depletion exist, so whether this represents a quantita- 
tive deficiency in the only pathway, or a qualitative deficiency of one of multiple 
pathways remains to be ascertained.  It is striking that even new borns,  who 
also had decreased amounts of the C-utilizing hemolysin for sheep cells,  were 
able  to  consume  a  greater per  cent  of the  available  C  than  were  the  AGG 
patients. GEWlmZ E~  AL.  825 
It has been found that AGG individuals are deficient in C1 and Clq (24, 32) 
as well as in gamma globulins generally. Hence, the ability of LPS to deplete 
C in these sera was compared with the C-depleting ability of immune complexes 
TABLE VI 
Formation  of C3-CP-Consuming  Intermediate  by  Incubation  of  Endotoxic  LPS  and  Serum 
for 15 Min at 37°C 
Serum source  Units  C3-C9 consumed*  C3-C9 consumed 
% 
Swiss-type AGG  < 50  < 10 
Bruton-type AGG  150  17 
Late-occurring AGG  180  21 
Normal newborn  220  26 
Normal adult  800  > 90 
* 860 units available. 
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FIO. 4.  V. alcalescens LPS (300 #g in 0.5 ml) was incubated for varying intervals at 37°C in 
0.5 ml of serum of normal, newborn, and agammaglobulinemic  individuals; the formation and 
decay of a classical C3 (C3-C9)-fixing intermediate on the LPS is shown. The agammaglobu- 
linic sera performed this function more poorly even than newborn sera. 
and CVF, neither of which require additional immunoglobulin  to deplete C  in 
normal sera. It can be seen in Fig. 3 that patients with AGG reacted normally 
to  both  these  agents.  This  is  compatible with  the  interpretation that  their 826  COMPLEMENT  INTERACTIONS  WITH  LPS 
FIG.  5.  Chemotactic  response  of rabbit  neutrophils  to  factor(s)  generated  by  5 
/~g of V. alcalescens LPS incubated in various pig sera (X 450).  (A) Preeolostral patho- 
gen-free,  disease-free  piglet serum  or maternal  serum  alone;  (B)  precolostral piglet 
serum (0.1 ml) pIus LPS; and (C) maternal serum (0.1 ml) plus LPS. 
decreased  ability  to  react  with  LPS  results  from  their  inmmnoglobulin  de- 
ficiency. 
The C-consuming efficiency of LPS in these sera was studied in still another 
way.  Shin et  al.  (28)  found that the interaction  of LPS and fresh mammalian 
serum  leads  to  formation  of  an  unstable  intermediate  provisionally  termed GEWURZ  ET  AL.  827 
"LPS-X", somewhat reminiscent of properdin-zymosan complex of Leon (33). 
LPS-X has the capacity to fix the classical third component of C  (C3-C9)  in 
the presence of EDTA. Assay of LPS-X formation allows comparing the ability 
of test sera to form a classical C3-fixing intermediate with the amount of ter- 
minal  C  components in  the  indictor step held constant,  an  important point 
since in the previous experiments there were larger amounts of C3-C9 available 
in the serum of older individuals. The ability of various human sera to form 
this intermediate with identical amounts of LPS was tested. It was found that 
AGG patients,  as well as new borns,  were deficient in their ability to do so 
(Fig.  4,  Table VI).  They formed much less  LPS-X than did  normal  adults. 
Hence, the role of immunoglobulin in formation of this intermediate,  and in 
consumption of C generally, seems likely. 
In parallel experiments, precolostral bovine and porcine sera were also found 
to be greatly inferior to normal adult sera of the respective species in forming 
the LPS-X complex. 
DISCUSSION 
It was found that bacterial endotoxins (LPS) could induce C consumption in 
a  wide variety of immunoglobulin-deficient sera,  including those from repre- 
sentative subjects with developmental AGG, experimentally-induced AGG and 
clinical AGG syndromes. The LPS-C interaction proceeded even in sera which 
contained less than 2.5 X  10  -6 ing/ml gamma globulin. Hence, large amounts of 
immunoglobulins  clearly  are  not  necessary  in  order  for  this  interaction  to 
proceed. However, whether small amounts of antibody either qualitatively not 
recognizable as immunoglobulin or quantitatively below the detection range of 
most assay systems were required to initiate these interactions remained un- 
certain. 
Various investigators have postulated that antibody is necessary for LPS to 
initiate certain of its various biologic effects including C consumption (34-36). 
Others have entertained the possibility that LPS contains groups either with 
direct toxicities or which activate host enzyme systems without mediation by 
antibody (37-40). The present investigation shows that if classical antibody is 
necessary for the initiation of the C-dependent portion of these host reactivities, 
then extremely small amounts suffice to satisfy this requirement. 
Certainly there is a question of whether classical antibodies are necessary at 
all to induce consumption of the terminal C components in normal and immuno- 
globulin-deficient sera. The existence of alternative pathways which lead to C 
activation without  a  requirement for antibody is  possible.  Pillemer  and  his 
colleagues earlier had postulated that there is such an alternative pathway (41), 
but ultimately showed that it,  too, was dependent upon antibody. However, 
various bacterial and mammalian enzymes have been shown to activate certain 
of the C components (42-44). More recently, work with a nontoxic factor de- 828  COMPLEMENT  INTERACTIONS WITH  LPS 
rived from several species of cobra (21, 45) has shown that the entire terminal 
C component sequence (C3-C9) can be activated by factors which seem not to 
include antibody or the earlier-acting C components (20, 46). Hence, it is con- 
ceivable that LPS can activate the terminal C  components without the pres- 
ence of antibody. 
At present, we favor the hypothesis that antibody is involved in the initiation 
of LPS-C  interactions.  The decreased total  amounts  of  C  consumed  in  the 
immunoglobulin-deficient  sera  compared  with  immunoglobulin-normal  sera, 
the decreased per cent, as well as total amount of C consumed in sera of patients 
with clinical AGG syndromes, the decreased amounts of neutrophil chemotactic 
factor and anaphylatoxin generated in immunoglobulin-deficient sera compared 
to  immunoglobulin-normal  sera,  and  the  markedly  impaired  ability  of  the 
immunoglobulin-deficient  sera  to  form  a  terminal  C  component-consuming 
intermediate (LPS-X), all support this view. However, this does not rule out 
that other nonimmunoglobulin-requiring pathways lead to consumption of the 
terminal C components. 
Hence, we believe that LPS efficiently interacts with trace amounts of im- 
munoglobulin in serum in a way which leads to consumption of the terminal C 
components. It does so in a way which consumes very small, if any, amounts of 
the known early-acting C components (C1, C4, and C2). Whether each of these 
also is involved in the C consumption induced by LPS, whether the basis of C 
utilization  by LPS  resides  in  a  particular  immunoglobulin,  in  other  serum 
proteins, or in special substrates in the LPS, and whether certain or all of the 
early-acting C components are bypassed in the LPS-C interaction, remains to 
be seen. 
In any case, the ability of LPS to consume C even in serum markedly deficient 
in  immunoglobulin  speaks  for  the  potential  role  of  the  LPS-C  interaction 
throughout development as well as in later life. 
SUMMARY 
Bacterial  lipopolysaccharides  (LPS)  derived  from  a  variety  of  organisms 
effectively induced C consumption in humans, bovines, and porcines with de- 
velopmental  agammaglobulinemia;  birds  with  experimental  agammaglobu- 
linemia;  and humans  with  agammaglobulinemia  syndromes. This interaction 
proceeded even in precolostral piglet sera which contained less than 2.5 >( 10  .6 
mg/ml gamma globulin, and led to generation of neutrophil chemotactic factor 
and anaphylatoxin in these sera. Hence, the LPS-C interaction can proceed in 
sera markedly deficient in immunoglobulin. 
The question of whether immunoglobulins can be bypassed  in  the LPS-C 
interaction, or whether they are regularly utilized in a way so efficient that their 
participation is masked, was considered. GEWVRZ ET  AL.  829 
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